May 5, 2008

QRx Pharma Releases successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy

Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company’s proposed products.

Disclaimer
This communication is not an offer, solicitation or specific recommendation with respect to the purchase or sale of any security, nor is it circulated to invite offers to purchase any security. It is for your general information only. The securities of QRxPharma have not been, and will not be, registered under the US Securities Act or the securities laws of any state of the United States. The securities of QRxPharma may not be offered, sold or resold in the United States or to, or for the account or benefit of, US Persons. 
 
For more information, log on to www.qrxpharma.com
CONTACT: Chris Campbell
CFO, QRxPharma
Mobile +61(0)401988444